IMVT: financial statements from SEC — TradeAlmanac

IMVT

Immunovant, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024
Selling, general and administrative	15m	18m	26m	20m	18m	19m
Operating expenses	114m	132m	127m	114m	116m	94m
Pre-tax income	−109m	−126m	−120m	−111m	−109m	−87m
Income tax	2m	594,000	913,000	152,000	78,000	77,000
Net income	−111m	−127m	−121m	−111m	−109m	−87m
Earnings per share	−0.61	−0.73	−0.71	−0.76	−0.74	−0.60
Earnings per share, diluted	−0.61	−0.73	−0.71	−0.76	−0.74	−0.60
Weighted average shares	182m	174m	171m	147m	146m	146m
Weighted average shares, diluted	182m	174m	171m	147m	146m	146m

Balance sheet

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024
Cash and equivalents	902m	995m	522m	599m	714m	375m	473m	560m
Receivables	1m	2m	2m

Cash flow

Metric	Jun 30, 2025	Jun 30, 2024
Operating cash flow	−117m	−76m
Depreciation and amortisation	107,000	80,000
Share-based compensation	19m	13m
Capital expenditure	0	182,000
Investing cash flow	0	−182,000
Financing cash flow	3m

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)